Literature DB >> 22999822

Kinesin family member 14 is a candidate prognostic marker for outcome of glioma patients.

Qi Wang1, Liang Wang, Daohai Li, Jianping Deng, Zhenwei Zhao, Shiming He, Yongsheng Zhang, Yanyang Tu.   

Abstract

BACKGROUND & AIM: Human kinesin superfamily proteins (KIFs) are a conserved class of microtubule-dependent molecular motor proteins with adenosine triphosphatase activity and motion characteristics. As a member of KIFs, KIF14 plays an important role in the regulation of cell cycle and mitotic progression. Deregulation of KIF14 has been found in several human malignancies and also has been demonstrated to be involved in tumor progression and related to patient survival. The aim of this study was to investigate the clinicopathological significance of KIF14 expression in glioma.
METHODS: Real-time quantitative RT-PCR assay was performed to detect KIF14 mRNA expression, and Western blot and immunohistochemistry analyses were performed to detect KIF14 protein expression in human gliomas and non-neoplastic brain tissues, respectively. Then, the association of KIF14 immunostaining with clinicopathological factors and prognosis of glioma patients was also statistically analyzed.
RESULTS: KIF14 mRNA and protein expression were respectively increased 5.5- and 4.2-fold on average in glioma tissues relative to non-neoplastic brain tissues (both P < 0.001). Additionally, both KIF14 mRNA and protein expression increased with ascending pathological grade. Then, the high KIF14 immunostaining in glioma tissues was significantly associated with advanced pathological grade (P = 0.008), low Karnofsky performance score (KPS) (P = 0.02), high mitotic index (P = 0.005) and Ki-67 index (P = 0.008). Furthermore, both univariate and multivariate Cox regression analyses determined that KIF14 overexpression effectively predicted decreased overall survival in patients with gliomas.
CONCLUSIONS: These findings offer the first convinced evidence that KIF14 expression in gliomas is tumor-specific and increased in more aggressive tumors. KIF14 might function as a candidate prognostic marker for human gliomas.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22999822     DOI: 10.1016/j.canep.2012.08.011

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  26 in total

1.  Centromere-associated protein E expresses a novel mRNA isoform in acute lymphoblastic leukemia.

Authors:  Cindy E Jiménez-Ávila; Vanessa Villegas-Ruíz; Marta Zapata-Tarres; Alejandra E Rubio-Portillo; Eleazar I Pérez López; Juan C Zenteno; Sergio Juárez-Méndez
Journal:  Int J Mol Epidemiol Genet       Date:  2018-10-20

2.  The kinesin KIF14 is overexpressed in medulloblastoma and downregulation of KIF14 suppressed tumor proliferation and induced apoptosis.

Authors:  Kay Ka-Wai Li; Yan Qi; Tian Xia; Aden Ka-Yin Chan; Zhen-Yu Zhang; Abudumijiti Aibaidula; Rong Zhang; Liangfu Zhou; Yu Yao; Ho-Keung Ng
Journal:  Lab Invest       Date:  2017-05-15       Impact factor: 5.662

3.  MiR-19a/miR-96-mediated low expression of KIF26A suppresses metastasis by regulating FAK pathway in gastric cancer.

Authors:  Ran-Ran Ma; Hui Zhang; Hong-Fang Chen; Guo-Hao Zhang; Ya-Ru Tian; Peng Gao
Journal:  Oncogene       Date:  2021-03-05       Impact factor: 9.867

Review 4.  A New Way to Treat Brain Tumors: Targeting Proteins Coded by Microcephaly Genes?: Brain tumors and microcephaly arise from opposing derangements regulating progenitor growth. Drivers of microcephaly could be attractive brain tumor targets.

Authors:  Patrick Y Lang; Timothy R Gershon
Journal:  Bioessays       Date:  2018-03-26       Impact factor: 4.345

5.  KIF14 promotes AKT phosphorylation and contributes to chemoresistance in triple-negative breast cancer.

Authors:  Stina M Singel; Crystal Cornelius; Elma Zaganjor; Kimberly Batten; Venetia R Sarode; Dennis L Buckley; Yan Peng; George B John; Hsiao C Li; Navid Sadeghi; Woodring E Wright; Lawrence Lum; Timothy W Corson; Jerry W Shay
Journal:  Neoplasia       Date:  2014-03       Impact factor: 5.715

6.  Sox17 inhibits hepatocellular carcinoma progression by downregulation of KIF14 expression.

Authors:  Tao Yang; Xiao-Na Li; Li Li; Qi-Mei Wu; Peng-Zhi Gao; Hong-Lei Wang; Wei Zhao
Journal:  Tumour Biol       Date:  2014-08-10

7.  The motor protein KIF14 inhibits tumor growth and cancer metastasis in lung adenocarcinoma.

Authors:  Pei-Fang Hung; Tse-Ming Hong; Yi-Chiung Hsu; Hsuan-Yu Chen; Yih-Leong Chang; Chen-Tu Wu; Gee-Chen Chang; Yuh-Shan Jou; Szu-Hua Pan; Pan-Chyr Yang
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

8.  Suppression of KIF3B expression inhibits human hepatocellular carcinoma proliferation.

Authors:  Xiaodong Huang; Fang Liu; Changlai Zhu; Jing Cai; Hua Wang; Xinxiu Wang; Song He; Cheng Liu; Li Yao; Zongmei Ding; Yixin Zhang; Tianyi Zhang
Journal:  Dig Dis Sci       Date:  2013-12-25       Impact factor: 3.199

9.  Transcriptional and epigenetic regulation of KIF14 overexpression in ovarian cancer.

Authors:  Brigitte L Thériault; Halesha D Basavarajappa; Harvey Lim; Sanja Pajovic; Brenda L Gallie; Timothy W Corson
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240

10.  Up-regulation of KIF14 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in cervical cancer.

Authors:  Wenjing Wang; Yanhua Shi; Jing Li; Wei Cui; Baozhi Yang
Journal:  Biosci Rep       Date:  2016-04-05       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.